This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
This article has an unclear citation style. The references used may be made clearer with a different or consistent style of citation and footnoting. (August 2013) (Learn how and when to remove this template message)
This article relies largely or entirely on a single source. Relevant discussion may be found on the talk page. Please help improve this article by introducing citations to additional sources.Find sources: "Catabasis Pharmaceuticals" – news · newspapers · books · scholar · JSTOR (November 2019)
(Learn how and when to remove this template message)
 | |
| Company type | Public |
|---|---|
| Nasdaq: CATB Russell Microcap Index component | |
| Industry | Pharmaceuticals |
| Founded | 2008 |
| Headquarters | Cambridge, Massachusetts |
Key people | Jill C. Milne (CEO)
Joanne M. Donovan (Chief Medical Officer) Andrew Nichols (Chief Scientific Officer), Deirdre A. Cunnane (Chief Legal Officer) |
| Products | Orally-delivered pharmaceuticals |
Number of employees | 24 (March 2019) |
Catabasis Pharmaceuticals, founded in 2008 and based in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company.[1] Their lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy.
In Catabasis’s Phase 2 MoveDMD clinical trial and open-label extension, edasalonexent was shown to preserve muscle function as assessed by the North Star Ambulatory Assessment and Timed Function Tests compared with the rate of change during an off-treatment control period. It also showed a significant decrease in CRP, muscle enzymes including CK, and decrease in heart rate to age-normative values.
